Hexosamine biosynthetic pathway flux and cardiomyopathy in type 2 diabetes mellitus . Focus on “Impact of type 2 diabetes and aging on cardiomyocyte function and O -linked N -acetylglucosamine levels in the heart”
2006; American Physical Society; Volume: 292; Issue: 4 Linguagem: Inglês
10.1152/ajpcell.00521.2006
ISSN1522-1563
Autores Tópico(s)Pancreatic function and diabetes
ResumoEDITORIAL FOCUSHexosamine biosynthetic pathway flux and cardiomyopathy in type 2 diabetes mellitus. Focus on "Impact of type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart"Patrick H. McNultyPatrick H. McNultyPublished Online:01 Apr 2007https://doi.org/10.1152/ajpcell.00521.2006This is the final version - click for previous versionMoreFiguresReferencesRelatedInformationPDF (39 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat the developed world is currently experiencing an epidemic of type 2 diabetes mellitus, with an estimated worldwide prevalence of >140 million cases (16). Among the end organs affected by diabetes is the myocardium, which has been demonstrated to exhibit a constellation of structural and functional abnormalities known collectively as diabetic cardiomyopathy. While historically it has been somewhat challenging to dissociate the effects of diabetes per se on the myocardium from those mediated by co-morbid conditions, studies applying Doppler echocardiographic techniques to both patients (9, 13) and rodent models of diabetes (1) have demonstrated generally consistent abnormalities of cardiac ventricular diastolic compliance attributable to cardiomyocyte hypertrophy, myocyte dropout, increased production of extracellular matrix, and impaired energy-dependent diastolic sequestration of intracellular calcium (7, 10). The effects of diabetes on the myocardium are perhaps less familiar to cardiovascular scientists and clinicians than its well-known effects on the coronary vasculature, yet diabetic cardiomyopathy nevertheless appears to have important clinical implications; for example, patients with diabetes have a substantially increased lifetime risk of congestive heart failure and are more than twice as likely to develop congestive heart failure in the setting of acute myocardial infarction as nondiabetic peers (16). These observations raise questions: does a predominant mechanism mediate the development of diabetic cardiomyopathy, and, if so, can its operation be suppressed pharmacologically?In this issue of AJP-Cell Physiology, Fülöp et al. (8; see p. 1370) report the latest in a productive series of examinations by their group and others of the hypothesis that increased flux of glucose carbon through the cardiomyocyte hexosamine biosynthetic pathway (HBP) is responsible for many of the manifestations of diabetic cardiomyopathy. Hexosamine biosynthesis normally represents only a minor alternative metabolic fate for glucose carbon at the fructose-6-phosphate step of glycolysis. However, HBP flux may increase under conditions of excess availability of exogenous glucose (when glucose is imported into cardiomyocytes in excess of their capacity to readily metabolize it via glycolysis and pyruvate oxidation) or free fatty acids (whose uptake and metabolism may inhibit pyruvate oxidation) (11, 12). Oxidative stress, another consistent feature of diabetes, may also increase HBP flux by inhibiting the operation of glyceraldehyde-3-phosphate dehydrogenase, the rate-limiting enzyme of glycolysis (2, 3, 6). The major product of the HBP, UDP-N-acetylglucosamine (UDP-GlcNAc), is the obligatory substrate for O-GlcNAc transferase (OGT), an enzyme that catalyzes the reversible O-GlcNAcylation of specific serine/threonine residues of numerous cytosolic and nuclear proteins (4). Posttranslational O-GlcNAcylation likely interferes with serine/threonine phosphorylation of these same proteins, thereby altering their function. Because protein substrates for OGT include broad-specificity nuclear transcription factors and insulin-responsive metabolic enzymes resident in the cytosol, the HBP has been hypothesized to function as a cellular "fuel gauge" in which increased HBP flux mediates the development of insulin resistance as a brake on excessive glucose consumption (4, 12).The significance of the HBP for diabetic cardiomyopathy resides in a broad series of recent observations in isolated cardiomyocytes and insulin-deficient rat models that demonstrate that cardiomyocyte excitation-contraction (E-C) coupling and ionotrophic reserve are sensitive to cellular levels of UDP-GlcNAc and, correspondingly, to the balance between the activities of OGT and its counterpart, O-GlcNAcase (5, 10, 14). These observations support the general premise that increased protein O-GlcNAcylation may mediate cardiac mechanical dysfunction in diabetes. However, a number of important points have remained uncertain, including whether this mechanism mediates the development of cardiomyopathy in the more clinically relevant condition of insulin-resistant (type 2) diabetes, and the relative importance of cellular UDP-GlcNAc concentration vs. OGT activity in mediating O-GlcNAcylation in the diabetic heart.In their new work, Fülöp and colleagues (8) report serial measurements of cardiac UDP-GlcNAc, O-GlcNAc-modified protein, and OGT expression, along with single-cell calcium transients and mechanical performance, during the transition from the insulin-resistant normoglycemic stage to the hyperglycemic stage in the Zucker diabetic fatty (ZDF) rat. This study represents an important extension of previous work, both in its comprehensive scope and in the attempt to characterize a rodent model of obesity and insulin resistance highly relevant to the increasingly prevalent form of human type 2 diabetes sometimes referred to as "diabesity." The transition from normoglycemia to hyperglycemia in ZDF rats was found to be associated with cellular accumulation of UDP-GlcNAc and O-GlcNAc-modified protein, delayed calcium sequestration, and impaired mechanical relaxation. However, OGT expression was no different in hyperglycemic ZDF rats than in hearts of age-matched lean control rats, suggesting that protein O-GlcNAcylation in this model may be predominantly substrate driven and therefore presumably determined by the magnitude of cardiomyocyte HBP flux.These observations demonstrate that increased cardiomyocyte HBP flux, with concomitantly increased protein O-GlcNAcylation, may contribute to the development of a specific cardiomyopathy in type 2 diabetes. Because both excess glucose availability and excess fatty acid availability can theoretically increase cardiomyocyte HBP flux, this mechanism would be a potential candidate to mediate the effects of both "glucose toxicity" and "lipotoxicity" on the diabetic heart (15, 16). Correspondingly, the observations of Fulop et al. (8) suggest that strategies to inhibit entry of glucose carbon into the HBP, either directly (e.g., by inhibiting the rate-limiting enzyme glutamine:fructose-6-phosphate amidotransferase; GFAT) or indirectly (e.g., by lowering circulating fatty acid or glucose levels, or stimulating glycolysis and/or pyruvate oxidation), might prevent or reverse the development of diabetic cardiomyopathy by reducing the level of cardiomyocyte O-GlcNAcylation and therefore its functional consequences.An interesting subsidiary observation of the current study of Fülöp et al. (8) is that O-GlcNAcylation in the hearts of hyperglycemic ZDF rats appeared to be largely limited to a high-molecular-weight band of cardiomyocyte protein. Characterization of the specific high-molecular-weight protein(s) involved, for example, determining whether these include contractile proteins or calcium channels, seems likely to shed additional light on the precise mechanism by which elevated circulating levels of glucose and free fatty acids impair cardiac E-C coupling. Given the recognized difficulty of trying to maintain circulating glucose and fatty acid levels normal over long periods of time in obese patients with type 2 diabetes, a pharmacological therapy targeted to the actual O-GlcNAcylation event responsible for conferring diabetic cardiac mechanical dysfunction would have obvious attraction.A number of important questions regarding the relationship between cardiomyocyte HBP flux and cardiac E-C coupling in diabetes remain to be answered. Among these are how insulin resistance and its attendant changes in substrate availability influence the expression or activities of the other enzymes involved, including perhaps most importantly GFAT and O-GlcNAcase; whether the relationships among cellular UDP-GlcNAc concentration, OGT expression, and O-GlcNAcylation are sensitive to ambient insulin level; and whether levels of heart O-GlcNAcylation continue to increase with increasing age in animals continuously exposed to a diabetic milieu. The ZDF rat, and other genetic models of obesity and insulin resistance, would seem a logical and potentially productive venue for the study of these questions.AUTHOR NOTESAddress for reprint requests and other correspondence: P. H. McNulty, Division of Cardiology, Bassett Healthcare, One Atwell Rd., Cooperstown, NY 13326 (e-mail: patrick.mcnulty@bassett.org) Download PDF Previous Back to Top Next FiguresReferencesRelatedInformationREFERENCES1 Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, Tsuji T, Kohzuki H, Suga H, Taniguchi S, Takaki M. Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats. Am J Physiol Heart Circ Physiol 282: H138–H148, 2002.Link | ISI | Google Scholar2 Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813–820, 2001.Crossref | PubMed | ISI | Google Scholar3 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615–1625, 2005.Crossref | PubMed | ISI | Google Scholar4 Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab 290: E1–E8, 2006.Link | ISI | Google Scholar5 Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukada M, Dillman WH. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278: 44230–44237, 2003.Crossref | PubMed | ISI | Google Scholar6 Du X, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M. Hyperglycemia-produced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97: 12222–12226, 2000.Crossref | PubMed | ISI | Google Scholar7 Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P. Myocardial cell death in human diabetes. Circ Res 87: 1123–1132, 2000.Crossref | PubMed | ISI | Google Scholar8 Fülöp N, Manson MM, Dutta K, Wang P, Davidoff AJ, Marchase RB, Chatham JC. Impact of type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart. Am J Physiol Cell Physiol 292: C1370–C1378, 2007.Link | ISI | Google Scholar9 Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham heart study). Am J Cardiol 68: 85–89. 1991.Crossref | PubMed | ISI | Google Scholar10 Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol Endocrinol Metab 244: E528–E535, 1983.Link | ISI | Google Scholar11 Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L. Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 99: 2173–2182, 1997.Crossref | PubMed | ISI | Google Scholar12 McClain DA. Hexosamines as mediators of nutrient sensing and regulation in diabetes. J Diabetes Complications 16: 72–80, 2002.Crossref | PubMed | ISI | Google Scholar13 Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24: 5–10, 2001.Crossref | PubMed | ISI | Google Scholar14 Ren J, Gintant GA, Miller RE, Davidoff AJ. High extracellular glucose impairs cardiac E-C coupling in a glycosylation-dependent manner. Am J Physiol Heart Circ Physiol 273: H2876–H2883, 1997.Link | ISI | Google Scholar15 Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 13: 610–630, 1990.Crossref | PubMed | ISI | Google Scholar16 Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes. Part I: general concepts. Circulation 105: 1727–1733, 2002.Crossref | PubMed | ISI | Google Scholar Cited ByRenin Angiotensin System in the Pathophysiology of Diabetic Cardiomyopathy in Type 2 Diabetes2 January 2023Role of Oxidative Stress in Diabetic Cardiomyopathy15 April 2022 | Antioxidants, Vol. 11, No. 4An Overview of Glycosylation and its Impact on Cardiovascular Health and Disease16 November 2021 | Frontiers in Molecular Biosciences, Vol. 8Glycation and Glycosylation in Cardiovascular Remodeling: Focus on Advanced Glycation End Products and O-Linked Glycosylations as Glucose-Related Pathogenetic Factors and Disease Markers19 October 2021 | Journal of Clinical Medicine, Vol. 10, No. 20Sensory Properties of Foods and Their Measurement Methods23 September 2021Nutrient regulation of signaling and transcriptionJournal of Biological Chemistry, Vol. 294, No. 7Targeting oxidative stress through antioxidants in diabetes mellitus8 January 2018 | Journal of Drug Targeting, Vol. 26, No. 9Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects11 January 2018 | Heart Failure Reviews, Vol. 23, No. 3Bio-tea prevents membrane destabilization during Isoproterenol-induced myocardial injuryJournal of Microscopy and Ultrastructure, Vol. 5, No. 3Dexamethasone-Induced Skeletal Muscle Atrophy Increases O-GlcNAcylation in C2C12 Cells2 February 2016 | Journal of Cellular Biochemistry, Vol. 117, No. 8Metabolic abnormalities of the heart in type II diabetes4 May 2015 | Diabetes and Vascular Disease Research, Vol. 12, No. 4Diabetic Cardiomyopathy and Oxidative StressExcess protein O-GlcNAcylation and the progression of diabetic cardiomyopathyEduardo S. Fricovsky, Jorge Suarez, Sang-Hyun Ihm, Brian T. Scott, Jorge A. Suarez-Ramirez, Indroneal Banerjee, Moises Torres-Gonzalez, Hong Wang, Irina Ellrott, Lisandro Maya-Ramos, Francisco Villarreal, and Wolfgang H. Dillmann1 October 2012 | American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, Vol. 303, No. 7Cardiac Transcription Factor Nkx2.5 Is Downregulated under Excessive O-GlcNAcylation Condition15 June 2012 | PLoS ONE, Vol. 7, No. 6Excessive O -GlcNAcylation of proteins suppresses spontaneous cardiogenesis in ES cells8 July 2009 | FEBS Letters, Vol. 583, No. 15Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and increased mitochondrial Bcl-2Voraratt Champattanachai, Richard B. Marchase, and John C. Chatham1 June 2008 | American Journal of Physiology-Cell Physiology, Vol. 294, No. 6Nonischemic heart failure in diabetes mellitusCurrent Opinion in Cardiology, Vol. 23, No. 3 More from this issue > Volume 292Issue 4April 2007Pages C1243-C1244 Copyright & PermissionsCopyright © 2007 the American Physiological Societyhttps://doi.org/10.1152/ajpcell.00521.2006PubMed17151141History Published online 1 April 2007 Published in print 1 April 2007 Metrics Downloaded 687 times 19 CITATIONS 19 Total citations 3 Recent citations 3.45 Field Citation Ratio 0.35 Relative Citation Ratio publications19supporting0mentioning14contrasting0Smart Citations190140Citing PublicationsSupportingMentioningContrastingView CitationsSee how this article has been cited at scite.aiscite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made. We recommend Hexosamines, insulin resistance, and the complications of diabetes: current status. Maria G Buse, American Journal of Physiology - Endocrinology and Metabolism, 2006 O-GlcNAcylation of connexin 40: a sweet connection between diabetes and endothelial cell dysfunction? Focus on "O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice" Tarik Issad et al., American Journal of Physiology - Cell Physiology, 2015 Glutamine enhances heat shock protein 70 expression via increased hexosamine biosynthetic pathway activity Christine R. Hamiel et al., American Journal of Physiology - Cell Physiology, 2009 Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity Ronald J. Copeland et al., American Journal of Physiology - Endocrinology and Metabolism, 2008 The hexosamine biosynthetic pathway and O-GlcNAcylation drive the expression of β-catenin and cell proliferation Stéphanie Olivier-Van Stichelen et al., American Journal of Physiology - Endocrinology and Metabolism, 2012 Assay for Hexosamine Pathway Intermediates (Uridine Diphosphate-N-Acetyl Amino Sugars) in Small Samples of Human Muscle Tissue Paul N Span et al., Clinical Chemistry, 2001 Modulation of O-GlcNAc Levels in the Liver Impacts Acetaminophen-Induced Liver Injury by Affecting Protein Adduct Formation and Glutathione Synthesis Steven R McGreal et al., Toxicological Sciences, 2018 AMPKα1 regulates Idh2 transcription through H2B O-GlcNAcylation during brown adipogenesis Yuxin Cao et al., Acta Biochimica et Biophysica Sinica, 2020 CHAPTER 4: Chemical Biology of O-GlcNAc Glycosylation Zhongping Tan et al., Royal Society of Chemistry Books, 2017 Deficiency of AtGFAT1 activity impairs growth, pollen germination and tolerance to tunicamycin in Arabidopsis Kien Van Vu et al., Journal of Experimental Botany, 2019 Powered by Targeting settings Do not sell my personal information Google Analytics settings I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). Learn more Yes No
Referência(s)